Visual outcome is similar in optic neuritis patients treated with oral and i.v. high-dose methylprednisolone: a retrospective study on 56 patients

BMC Neurol. 2018 Sep 29;18(1):160. doi: 10.1186/s12883-018-1165-6.

Abstract

Background: To investigate visual recovery after treatment of acute optic neuritis (ON) with either oral or intravenous high-dose methylprednisolone, in order to establish the best route of administration.

Methods: Retrospective analysis of patients treated with oral or intravenous high-dose (≥500 mg per day) methylprednisolone for acute ON of unknown or demyelinating etiology. Twenty-eight patients were included in each treatment group. Visual acuity was measured with the Snellen letter chart, color vision with Boström-Kugelberg pseudo-isochromatic plates, and visual field with a Humphrey Field Analyzer.

Results: The treatment results were similar in the two groups at follow-up, with no significant difference in visual acuity (p = 0.54), color vision (p = 0.18), visual field mean deviation (p = 0.39) or the number of highly significantly depressed test points (p = 0.46).

Conclusions: The results show no clinical disadvantage of using oral high-dose corticosteroids compared to intravenous administration in the treatment of acute ON, which would facilitate the clinical management of these patients.

Keywords: Corticosteroids; Methylprednisolone; Multiple sclerosis; Optic neuritis.

MeSH terms

  • Administration, Oral*
  • Adolescent
  • Adult
  • Female
  • Glucocorticoids / administration & dosage
  • Glucocorticoids / pharmacology*
  • Humans
  • Infusions, Intravenous*
  • Male
  • Methylprednisolone / administration & dosage
  • Methylprednisolone / pharmacology*
  • Middle Aged
  • Optic Neuritis / complications
  • Optic Neuritis / drug therapy*
  • Outcome Assessment, Health Care*
  • Retrospective Studies
  • Vision Disorders / drug therapy*
  • Vision Disorders / etiology
  • Young Adult

Substances

  • Glucocorticoids
  • Methylprednisolone